EcoDrugPlus

Solute Carrier Family 9 Member A3

Ensembl ID : ENSNFUG00015022957
Gene Symbol: SLC9A3
3 Cross references
234 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSNFUG00015015950
Gene Symbol: SSTR2
3 Cross references
192 Possible Orthologues:

Somatostatin Receptor Type 2-Like

Ensembl ID : ENSNFUG00015003904
Gene Symbol: LOC107376458
3 Cross references
192 Possible Orthologues:

Somatostatin Receptor Type 5-Like

Ensembl ID : ENSNFUG00015004907
Gene Symbol: LOC107375151
2 Cross references
183 Possible Orthologues:

Sphingosine Kinase 2

Ensembl ID : ENSNFUG00015011008
Gene Symbol: SPHK2
2 Cross references
200 Possible Orthologues:

Sphingosine-1-Phosphate Receptor 1

Ensembl ID : ENSNFUG00015006101
Gene Symbol: S1PR1
3 Cross references
200 Possible Orthologues:

Spleen Associated Tyrosine Kinase

Ensembl ID : ENSNFUG00015003624
Gene Symbol: SYK
3 Cross references
200 Possible Orthologues:

Steroid-5-Alpha-Reductase, Alpha Polypeptide 2b

Ensembl ID : ENSNFUG00015016193
Gene Symbol: SRD5A2B
1 Cross references
191 Possible Orthologues:

Sterol O-Acyltransferase 1

Ensembl ID : ENSNFUG00015023165
Gene Symbol: SOAT1
1 Cross references
210 Possible Orthologues:

Substance-P Receptor-Like

Ensembl ID : ENSNFUG00015007292
Gene Symbol: LOC107395595
3 Cross references
193 Possible Orthologues:

Synuclein Alpha

Ensembl ID : ENSNFUG00015000931
Gene Symbol: SNCA
1 Cross references
7 Possible Orthologues:

Tachykinin Receptor 2

Ensembl ID : ENSNFUG00015003366
Gene Symbol: TACR2
1 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).